Interestingly, an Lm-based vaccine expressing a multivalent HCC tumor antigen, Lmdd-MPFG, can induce PD-L1 expression, the ligand for PD-1, in HCC tumor cells suggesting that it may synergize with ICI therapy (108). This evidence concerns the gene CD274 and hepatocellular carcinoma.